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Retinoic acid receptor-a in
HIV-associated nephropathy
To the Editor: We have read the paper by Ratnam et al.1
reporting that the expression of retinoic acid receptor-a
(RARA) target genes were suppressed in the kidneys of
HIV-1 transgenic mice (TG26), as well as those of patients
with HIV-associated nephropathy (HIVAN). The overall enzy-
matic activity for retinoic acid synthesis was signiﬁcantly
reduced in the glomeruli of TG26 mice, suggesting that a
defect in the synthesis of retinoic acid contributed to loss
of protection by retinoic acid in HIVAN. They postulated that
RARA agonists may be potential agents for treatment of
HIVAN.
In this regard, we would like to share a similar ﬁnding
with our recent work2 in IgA nephropathy (IgAN). Using
the GeneChip Human Genome U133 Plus 2.0 Arrays from
Affymetrix (Santa Clara, CA), a total of 7761 gene expressions
were identiﬁed that had an IgAN/normal gene expression
ratio of 0.06- to 5.58-fold (312 were upregulated with a
ratio X2.0-fold and 244 were downregulated with a ratio
p0.2-fold). An analysis of the expression of the 30 most
downregulated genes revealed that RARA was most down-
regulated in IgAN. Comparing the gene expression proﬁle of
patients with IgAN, non-IgAN (minimal change disease), and
normal controls, the RARA gene expression proﬁle was found
to be downregulated to 0.41-fold (231±77 vs 561±227 units,
Po0.005) in patients with IgAN compared with patients and
normal controls. Our ﬁnding of downregulation of RARA in
IgAN is similar to the ﬁnding of Ratnam et al.1 of suppression
of RARA target gene expression in TG26 mice and HIVAN
patients.
The ﬁnding of downregulating of mRNA expression for
RARA in IgAN may suggest a potential therapeutic approach
for IgAN. Shaier’s model of Thy-GN mice3 is akin to the
human disease of IgAN, as the Thy-GN mice have mesangial
proliferative glomerulonephritis (GN) similar to human
IgAN where there is also mesangial proliferative GN. In
Shaier’s report,3 Thy-GN mice treated with RARA agonist
had reduced proteinuria and normalization of blood pressure.
We postulate that RARA-speciﬁc retinoids may provide a
therapeutic approach to the therapy of IgAN. RARA belongs
to the steroid hormone superfamily of nuclear receptor
proteins, which exert their effects by binding speciﬁc DNA
response elements, thus regulating gene expression I target
cells.4,5 Regulating or normalizing RARA mRNA expression
in patients with IgAN may thus offer a novel therapeutic
approach in terms of gene therapy. This is especially relevant
to IgAN, which has hitherto no known speciﬁc therapy. In
this respect, we are in complete agreement with Ratnam’s
postulate that RARA agonists may be potential agents for
treatment of HIVAN.1
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The Authors Reply: Woo et al1 performed a GeneChip
microarray using total leukoctye ribonucleic acid isolated
from patients with IgA nephropathy compared with those
with minimal change disease and normal controls. Through
this unbiased screening, they ﬁnd that retinoic acid receptor-a
(RARA) mRNA level is downregulated to 0.41-fold in patients
with IgA nephropathy compared with patients with minimal
change disease and normal controls. Their ﬁndings suggest
an important role of RARA and retinoic acid signaling
in patients with kidney disease. The role of retinoic acid
has been demonstrated in many animal models of kidney
disease.2 However, the studies of retinoic acid and RARA
in human disease are lacking. It would be interesting to
determine RARA expression in kidneys of patients with
IgA nephropathy and other kidney diseases. We were not
able to determine the level of RARA mRNA in kidneys
of patients with HIV-associated nephropathy. By immuno-
staining, we did not observe a difference in RARA in the
kidney between patients with HIV-associated nephropathy
and minimal change disease. Our data suggest that RARA-
mediated target gene expression is suppressed in kidneys
of HIV-1 transgenic mice because of impaired endo-
genous retinoic acid synthesis. Consistent with our ﬁndings,
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